Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2INDIV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 12Sarcoma 4Gynecologic 2Other solid neoplasm 1Genitourinary 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 1Endometrial Neoplasms 1

Interventions

Paclitaxel 268Carboplatin 264Cisplatin 194Bevacizumab 135pembrolizumab 99Surveys and Questionnaires 84Radiotherapy 77Cyclophosphamide 75olaparib 67Blood Specimen Collection 65Drug Therapy 62Hyperthermic Intraperitoneal Chemotherapy 60Gemcitabine 60niraparib 56Topotecan 56Brachytherapy 54liposomal doxorubicin 52Taxes 47Docetaxel 46Magnetic Resonance Spectroscopy 43Letrozole 36Cytoreduction Surgical Procedures 36Filgrastim 33Biopsy 33Surgical Procedures, Operative 32durvalumab 31Specimen Handling 31Doxorubicin 31Nivolumab 30Albumin-Bound Paclitaxel 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × PM 01183 × Gynecologic × Clear all
NCT05636111 2026-01-22

Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

M.D. Anderson Cancer Center

Phase 1 Recruiting
34 enrolled
Gynecologic

Ovarian Neoplasms

NCT06385548 2025-04-01

LiDer

Vall d'Hebron Institute of Oncology

Phase 1/2 Withdrawn
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡